Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 5/2012

01-05-2012 | Letter to the Editor

Some concerns about the article: "High doses of oxycodone–naloxone combination may provide poor analgesia."

Authors: Christian Compagnone, Fernanda Tagliaferri, Andrea Ramelli

Published in: Supportive Care in Cancer | Issue 5/2012

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Mercadante S, Ferrera P, Adile C (2010) High doses of oxycodone–naloxone combination may provide poor analgesia. Support Care Cancer 19:1471–1472CrossRef
2.
3.
Varrassi G, Muller-Schwefe G, Pergolizzi J et al (2010) Pharmacological treatment of chronic pain—the need for CHANGE. Curr Med Res Opin 26:1231–1245PubMedCrossRef
4.
Leppert W (2010) Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep 62:578–591PubMed
5.
Ahmedzai S, Kremers W, Bosse B, Hopp M and Reimer K (2011) A randomized, double-blind, active-controlled, double-dummy, parallel group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in subjects with moderate to severe, chronic cancer pain. 12th Congress of the European Association for Palliative Care, Abstract number: P384.
6.
Nolte T (2011) Prolonged-release oxycodone/naloxone is effective and well tolerated in the treatment of cancer pain. 12th Congress of the European Association for Palliative Care, Abstract number: P382.
7.
Vondrackova D, Leyendecker P, Meissner W et al (2008) Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 9:1144–1154PubMedCrossRef
8.
Simpson K, Leyendecker P, Hopp M et al (2008) Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 24:3503–3512PubMedCrossRef
9.
Lowenstein O, Leyendecker P, Hopp M et al (2009) Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 10:531–543PubMedCrossRef
10.
Schutter U, Grunert S, Meyer C, Schmidt T, Nolte T (2010) Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 26:1377–1387PubMedCrossRef
Metadata
Title
Some concerns about the article: "High doses of oxycodone–naloxone combination may provide poor analgesia."
Authors
Christian Compagnone
Fernanda Tagliaferri
Andrea Ramelli
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 5/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1346-y

Other articles of this Issue 5/2012

Supportive Care in Cancer 5/2012 Go to the issue

Short Communication

Savene® (dexrazoxane) use in clinical practice

Review Article

Assessing the body image: relevance, application and instruments for oncological settings

Original Article

Knowledge, beliefs, and concerns about opioids, palliative care, and homecare of advanced cancer patients: a nationwide survey in Japan

Original Article

Fatigue in advanced cancer patients attending an outpatient palliative radiotherapy clinic as screened by the Edmonton Symptom Assessment System

Original Article

Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy

Review Article

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits